ABSTRACT BACKGROUND There is no nonparenteral medication for the rapid termination of paroxysmal supraventricular
NODE-1 (Efficacy and Safety of Intranasal MSP-2017
[Etripamil] for the Conversion of PSVT to Sinus Rhythm) was a phase 2 study designed to demonstrate the superiority of etripamil over placebo for the acute termination of SVT in the electrophysiology laboratory, evaluate the safety of etripamil, and identify dose(s) to be tested in future phase 3 studies to be conducted outside the hospital environment.
METHODS
STUDY DESIGN AND PATIENTS. NODE-1 (NCT02296190) was a multicenter, randomized, double-blind, placebocontrolled, dose-ranging study designed to evaluate the effects of etripamil nasal spray in male and female patients 18 years of age and older with documented histories of SVT who were scheduled to undergo electrophysiological studies prior to planned catheter ablation. The exclusion criteria were a history of adverse reaction to intravenous (IV) verapamil, a significant or chronic condition of the nasal cavity that would interfere with intranasal drug administration, systolic blood pressure (SBP) <100 mm Hg or diastolic blood pressure <50 mm Hg at screening or at the treatment visit, history or evidence of congestive heart failure (except New York Heart Association functional class I) or pulmonary edema, a prolonged Bazettcorrected QT interval (>455 ms), ventricular preexcitation, second-or third-degree atrioventricular block, pregnancy, breastfeeding, failure to agree to use an acceptable form of contraception, concomitant use of certain medications (e.g., digoxin, class I to IV antiarrhythmic drug), and documentation of an arrhythmia other than SVT.
This study was carried out in accordance with In- Before attempted induction of SVT, vital signs, consisting of blood pressure and heart rate, were recorded, and a continuous surface rhythm strip was obtained. Baseline vital signs were the averages of the measurements taken 10 and 20 min before SVT induction, and the time 0 vital signs were the averages of the measurements during SVT between 5 and 0 min before study drug administration. Sedation could be given during the study via single or multiple administrations using minimally necessary doses of benzodiazepines and/or narcotics at the investigator's discretion, but a continuous sedative or analgesic or inhaled anesthetic drug was not permitted until minute 30 after study drug administration.
SVT INDUCTION. Induction of SVT was attempted using standard pacing and programmed stimulation methods. If SVT could not be induced after a reasonable number of attempts, or could be induced but did not sustain for 5 min, IV isoproterenol was infused at a rate of 1 mg/min, and attempts to induce SVT were repeated. If SVT induction was unsuccessful with isoproterenol 1 mg/min, the infusion rate could be increased. If isoproterenol was used, a surface rhythm strip was collected once the heart rate had stabilized. If induction was successful with STATISTICAL METHODS. Efficacy analyses were performed in randomized patients in whom SVT was induced and sustained for 5 min, had received study drug, and completed the assessment of conversion to sinus rhythm (i.e., evaluable population). Safety analyses were based on all randomized patients who were induced into SVT and received study drug.
S a m p l e s i z e d e t e r m i n a t i o n . It was expected that there would be a 50 percentage point difference in the SVT conversion rate between patients receiving placebo and any dose of etripamil within 15 min after study drug administration (i.e., 30% for placebo, 80% for etripamil). Accounting for a 2-sided test with a type I error rate of a ¼ 0.05, 20 patients per group provided 84% power when using the Fisher exact test. Therefore, a sample size of at least 100 evaluable patients (i.e., at least 20 evaluable patients per group) was considered appropriate to meet study objectives. and 13 patients (i.e., 33% of the study population).
S t a t i s t i c
The percentage of patients dosed by number of patients per site is shown in Figure 1 . Figure 2) .
Overall, no differences in conversion rates were observed on the basis of the administration or lack of administration of isoproterenol.
Time to conversion from SVT to sinus rhythm. For the 3 etripamil doses with statistically significant conversion rates compared with placebo (70, 105, and 140 mg), the time at which 50% of patients converted In the placebo group and the combined active substance groups, the minimum mean heart rates (84.7 and 82.4 beats/min, respectively) were similar.
The minimum heart rate in any individual patient occurring within 30 min after study drug adminis- Patients who did not convert within 15 min after study drug administration were censored at 15 min. 
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